Orally consumed viable bacteria with proposed beneficial health effects, the so-called probiotics, are increasingly used to treat disorders of the gastrointestinal tract. It has been recently suggested that specifically selected lactobacilli could have a therapeutic role in female urogenital tract infections. It has been also suggested that some of these bacteria could be not intravaginally instilled, but also orally delivered. The authors investigate the ability of lactobacilli isolated from the vagina to survive gastrointestinal tract transit, and establish a link between the rate of intestinal survival and vaginal colonization.
P robiotics or orally consumed viable bacteria with proposed beneficial health effects are increasingly used to treat disorders of the gastrointestinal tract as well as female urogenital infections. 1 A scientific consensus 2, 3 has been reached, at least in general terms, on the properties that a bacterial strain must have to be further assayed for a probiotic use:
• It must be of human origin.
• It must survive during gastric transit.
• It has to tolerate bile salts.
• It has to adhere to gut epithelial tissue.
The first criterion takes into consideration the original habitat of the bacteria to be selected for probiotic use, as it seems reasonable, and it is supported by experimental evidence 2 that bacteria isolated from a given environment have a better chance to outcompete indigenous bacteria and establish themselves at a numerically significant level in their original living host. However, this criterion is lacking a molecularbased explanation, and some questions are still not answered. For example, it could be pointed out that Lactobacillus gasseri strains are commonly isolated not only from the human gut but also from the urogenital tract. 4, 5 Currently it not possible to discriminate between intestinal and vaginal isolates belonging to the same species. This problem also raises the point of the relationship between the intestinal and vaginal ecosystem-if there is or is not a direct connection, and if the same strain could inhabit both sites. An answer to this question could be helpful in explaining the recently reported evidence of the possibility of delivering probiotic lactobacilli to the vagina via an oral route. [6] [7] [8] The strains used have been isolated from the vaginal tract. Thus, it is unclear whether they are able to survive during transit through the gastrointestinal tract. We report the results of a double-blind human trial aimed at establishing the presence of L. rhamnosus GR-1 and L. fermentum RC-14 not only in vaginal swabs, but also in fecal samples, to provide information on the possible link between intestinal and vaginal colonization rates.
MATERIALS AND METHODS

Bacterial Strains
L. rhamnosus GR-1 and L. fermentum RC-14 were the strains of choice, because they originate from the female urogenital tract, and they have already been shown to colonize the vagina even when administered orally. They were produced and packed as freeze-dried preparations by Probiotical (Novara, Italy).
The study subjects included 10 women with no history of urogenital infection in the previous 12 months, no urogenital abnormalities, not taking any medication, and all reported being in full health. They were randomly allotted to receive either a probiotic preparation (n = 8) containing L. rhamnosus GR-1 and L. fermentum RC-14 or lactose placebo (n = 2) by mouth once daily for 14 days. Each subject read, understood, and signed a consent form. The subjects and investigators were Swabs and fecal samples were diluted in saline solution and cultured on Rogosa acetate agar (Difco) with the same medium added with 12 µg/mL vancomycin. Plates were anaerobically incubated at 37°C for 48 hours.
Genetic Identification
Randomly selected CFU of lactobacilli (about 10% of colonies counted on readable plates, containing 25-250 CFU) grown on Rogosa acetate agar with vancomycin were isolated and cultivated in MRS broth (Difco) to perform species and strain identification. Bacterial cells were then collected from 1 mL overnight cultures by centrifugation, washed with 1 mL sterile water, centrifuged again, and suspended in 1 mL sterile, ultrapure water. DNA was extracted by means of the Puregene Gentra Kit (Celbio), following the manufacturer's instructions. Identification of L. rhamnosus at the species level was achieved by species-specific 9 PCR amplification using primers Y2 (5Ј-CCC ACT GCT GCC TCC CGT AGG AGT-3Ј) and RHAM (5Ј-TGC ATC TTG ATT TAA TTT TG-3Ј). The following amplification cycle was used: 1 cycle at 94°C for 4 minutes; followed by 25 cycles at 94°C for 30 seconds, 45°C for 30 seconds, and 72°C for 30 seconds; and 1 final cycle at 72°C for 7 minutes. The amplification products (about 290 bp) were subjected to gel electrophoresis in 1% agarose at 100 V, followed by ethidium bromide staining.
To identify L. fermentum at the species level, because species-specific primers are not available, we used the rapid amplified ribosomal DNA restriction analysis (ARDRA) technique. 10 The 16S rDNA amplified was digested with Sau 3AI restriction enzyme (Promega), and the digested products were subjected to gel electrophoresis in 2.5% agarose at 100 V, followed by ethidium bromide staining.
To identify L. rhamnosus GR-1 and L. fermentum RC-14 at the strain level, a REP-PCR was performed using the primer RW3A (5Ј-TCG CTC AAA ACA ACG ACA CC-3Ј).
11 Amplifications were performed with the following temperature profiles: 1 cycle at 95°C for 7 minutes, 45 cycles at 90°C for 30 seconds, 45°C for 1 minute, 65°C for 8 minutes; and 1 final cycle at 65°C for 16 minutes. The amplification products were subjected to 1.8% agarose gel electrophoresis at 100 V, followed by ethidium bromide staining.
RESULTS
Microbiologic Counts
Results of plate counts are reported in Tables 1 and 2 . Fecal samples showed, during the treatment period, a significant increase in vancomycin-insensitive lactobacilli in 8 of 10 subjects (with the exception of patient nos. 6 and 8). No persistence at T = 21 was detected. Vaginal swabs showed an increase in lactobacilli in the same 8 subjects, but in 3 of 8 the difference was minimal. A direct correlation between the rate of increase in the fecal samples and variation in vaginal swabs was not observed.
Genetic Identification
A total of 175 CFU among those grown in Rogosa acetate added with vancomycin were selected for species and strain identification. Examples of REP-PCR identification are provided in Figures 1 and 2 . To confirm the identification further, ARDRA analysis was performed on all CFU positively identified as L. rhamnosus GR-1 or L. fermentum RC-14 (Fig. 3) .
Genetic typing allowed us to identify at least in 1 sampling point L. rhamnosus GR-1 in 8 subjects (fecal samples) and in 5 subjects (vaginal swabs). L. fermentum RC-14 was identified in fecal samples of 4 subjects and in 2 vaginal swabs. In 2 subjects it was not possible to identify in vaginal swabs either L. rhamnosus GR-1 or L. fermentum RC-14. In patient nos. 6 and 8 were negative for the presence of both strains in all samples. When codes were broken, it turned out that these subjects were the placebo-treated ones (Table 3) .
DISCUSSION
This study demonstrated that L. rhamnosus GR-1 and L. fermentum RC-14 can be delivered to the vaginal environment even if they are taken orally. Their administration resulted in significant changes in the vaginal flora in terms of increased lactobacilli presence, mainly the vancomycin-insensitive part of the bacterial population, which comprise the species L. rhamnosus and L. fermentum. The study protocol was not designed to be mechanism based, but the results indicate that oral delivery of these strains led to colonization of vaginal microflora. Our results do not suggest a direct link between the level of recovery of the 2 studied strains in fecal samples and the rate of vaginal colonization. A high presence in fecal samples does not necessarily correspond to a high presence in vaginal swabs. Moreover, vaginal colonization seems to occur mainly during the second week of administration. However, L. rhamnosus GR-1 seems to be more efficient in both intestinal and vaginal colonization, whereas L. fermentum RC-14 seems to be slightly less efficient.
Results are promising but not really unexpected, because these strains, originally isolated from the urogenital tract, have been shown to be good gut colonizers. 12 These observations raise the problem of the relationship between the intestinal and vaginal lactic flora. What it is now clear is that some strains of lactobacilli can inhabit the human gut as well as the urogenital tract, and that from the gut to the vagina, a passage is possible. 
